Catalyst Pharmaceuticals (CPRX) Accumulated Depreciation & Amortization (2016 - 2025)
Catalyst Pharmaceuticals (CPRX) has disclosed Accumulated Depreciation & Amortization for 14 consecutive years, with -$604000.0 as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Accumulated Depreciation & Amortization fell 98.68% year-over-year to -$604000.0, compared with a TTM value of -$604000.0 through Dec 2025, down 98.68%, and an annual FY2025 reading of -$604000.0, down 98.68% over the prior year.
- Accumulated Depreciation & Amortization was -$604000.0 for Q4 2025 at Catalyst Pharmaceuticals, up from -$644000.0 in the prior quarter.
- Across five years, Accumulated Depreciation & Amortization topped out at $98000.0 in Q3 2022 and bottomed at -$847000.0 in Q4 2022.
- Average Accumulated Depreciation & Amortization over 5 years is -$339312.5, with a median of -$270000.0 recorded in 2024.
- Peak annual rise in Accumulated Depreciation & Amortization hit 152.0% in 2022, while the deepest fall reached 4133.33% in 2022.
- Year by year, Accumulated Depreciation & Amortization stood at $21000.0 in 2021, then plummeted by 4133.33% to -$847000.0 in 2022, then surged by 75.91% to -$204000.0 in 2023, then tumbled by 49.02% to -$304000.0 in 2024, then plummeted by 98.68% to -$604000.0 in 2025.
- Business Quant data shows Accumulated Depreciation & Amortization for CPRX at -$604000.0 in Q4 2025, -$644000.0 in Q3 2025, and -$73000.0 in Q2 2025.